{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:55:43Z","timestamp":1780491343838,"version":"3.54.1"},"reference-count":213,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Health-related quality of life (HRQoL) describes an individual's perception of the impact of health, disease, and treatment on their quality of life (QoL). It is a reflection of how the manifestation of an illness and its treatment is personally experienced. Assessing HRQoL is particularly important in sarcoidosis because the attributable disease mortality is relatively low, and one of the major reasons for initiating treatment is to improve quality of life. HRQoL has been assessed in sarcoidosis using various generic and sarcoid-specific patient-reported outcome measures (PROMs). It is important that both the direct and indirect effects of the disease, as well as potential toxicities of therapy, are captured in the various PROMs used to assess HRQoL in sarcoidosis. This article provides a general overview of HRQoL in patients with sarcoidosis. It describes the various PROMs used to assess HRQoL in sarcoidosis and addresses the various factors that influence HRQoL in sarcoidosis. Specific attention is paid to fatigue, small fiber neuropathy, corticosteroid therapy, and other disease-specific factors that affect HRQoL in sarcoidosis. It also provides an insight into interventions that have been associated with improved HRQoL in sarcoidosis and offers suggestions for future research in this important area.<\/jats:p>","DOI":"10.1055\/s-0040-1710080","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:54:11Z","timestamp":1593046451000},"page":"716-732","source":"Crossref","is-referenced-by-count":14,"title":["Health-Related Quality of Life in Sarcoidosis"],"prefix":"10.1055","volume":"41","author":[{"given":"Ogugua Ndili","family":"Obi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1378\/chest.127.1.284","article-title":"Health-related quality of life among patients with idiopathic pulmonary fibrosis","volume":"127","author":"J J Swigris","year":"2005","journal-title":"Chest"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4081\/hpr.2013.932","article-title":"Quality of life in chronic disease patients","volume":"1","author":"K Megari","year":"2013","journal-title":"Health Psychol Res"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02841860260088764","article-title":"Quality-of-life assessment in oncology. Achievements and challenges","volume":"41","author":"M A Sprangers","year":"2002","journal-title":"Acta Oncol"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccm.2015.08.014","article-title":"Quality of life assessment in sarcoidosis","volume":"36","author":"M A Judson","year":"2015","journal-title":"Clin Chest Med"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jama.2011.10","article-title":"Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics","volume":"305","author":"M C Iannuzzi","year":"2011","journal-title":"JAMA"},{"issue":"02","key":"ref7","first-page":"736","article-title":"Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1183\/13993003.00991-2017","article-title":"Phenotypes of organ involvement in sarcoidosis","volume":"51","author":"J C Schupp","year":"2018","journal-title":"Eur Respir J"},{"issue":"02","key":"ref9","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"M A Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"R P Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment","volume":"51","author":"G J Gibson","year":"1996","journal-title":"Thorax"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1183\/09031936.00060612","article-title":"Established and experimental medical therapy of pulmonary sarcoidosis","volume":"41","author":"R P Baughman","year":"2013","journal-title":"Eur Respir J"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"B P McKinzie","year":"2010","journal-title":"Am J Med Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.rmed.2017.12.009","article-title":"Steroids for sarcoidosis: How much and for how long?","volume":"138S","author":"R P Baughman","year":"2018","journal-title":"Respir Med"},{"key":"ref15","first-page":"325","article-title":"Current and emerging pharmacological treatments for sarcoidosis: a review","volume":"7","author":"S H Beegle","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","article-title":"Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study","volume":"104","author":"A C Schutt","year":"2010","journal-title":"Respir Med"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in Sarcoidosis","volume":"42","author":"M A Judson","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"N A Khan","year":"2017","journal-title":"Respir Med"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"D Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.rmed.2017.10.022","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis","volume":"138S","author":"C E Broos","year":"2018","journal-title":"Respir Med"},{"issue":"03","key":"ref21","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","author":"R P Baughman","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1183\/09031936.06.00105805","article-title":"Corticosteroid treatment in sarcoidosis","volume":"28","author":"J C Grutters","year":"2006","journal-title":"Eur Respir J"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/thx.2006.062836","article-title":"Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK","volume":"61","author":"J Gribbin","year":"2006","journal-title":"Thorax"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1378\/chest.121.1.32","article-title":"Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy","volume":"121","author":"J M Reich","year":"2002","journal-title":"Chest"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"J J Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis","volume":"99","author":"R P Baughman","year":"2006","journal-title":"QJM"},{"issue":"04","key":"ref27","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Wells law","volume":"34","author":"R P Baughman","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.rmed.2012.01.013","article-title":"The treatment of pulmonary sarcoidosis","volume":"106","author":"M A Judson","year":"2012","journal-title":"Respir Med"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: patient treatment priorities","volume":"4","author":"R P Baughman","year":"2018","journal-title":"ERJ Open Res"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"C E Cox","year":"2004","journal-title":"Chest"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0954-6111(98)90007-5","article-title":"Evaluation of quality of life in sarcoidosis patients","volume":"92","author":"R M Wirnsberger","year":"1998","journal-title":"Respir Med"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejim.2006.02.024","article-title":"Quality of life in patients with active sarcoidosis in Greece","volume":"17","author":"K M Antoniou","year":"2006","journal-title":"Eur J Intern Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2016.02.011","article-title":"The three tiers of screening for sarcoidosis organ involvement","volume":"113","author":"M A Judson","year":"2016","journal-title":"Respir Med"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.130.4.989","article-title":"Fatigue is associated with quality of life in sarcoidosis patients","volume":"130","author":"H J Michielsen","year":"2006","journal-title":"Chest"},{"issue":"02","key":"ref35","first-page":"124","article-title":"Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids","volume":"33","author":"A N Aggarwal","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref36","first-page":"59","article-title":"Quality of life and depressive symptoms in patients suffering from sarcoidosis","volume":"15","author":"M Drent","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm.163.2.2004177","article-title":"Depression in sarcoidosis","volume":"163","author":"B Chang","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"ref38","first-page":"256024","article-title":"Sarcoidosis and pain caused by small-fiber neuropathy","volume":"2012","author":"L Heij","year":"2012","journal-title":"Pain Res Treat"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","author":"J Tavee","year":"2011","journal-title":"Curr Pain Headache Rep"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000314225","article-title":"Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment","volume":"80","author":"M D Elfferich","year":"2010","journal-title":"Respiration"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ccm.2015.08.013","article-title":"Consequences of sarcoidosis","volume":"36","author":"M Drent","year":"2015","journal-title":"Clin Chest Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study","volume":"138S","author":"C Hendriks","year":"2018","journal-title":"Respir Med"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12016-014-8450-y","article-title":"The clinical features of sarcoidosis: a comprehensive review","volume":"49","author":"M A Judson","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"issue":"02","key":"ref44","first-page":"155","article-title":"The burden of sarcoidosis symptoms from a patient perspective","volume":"197","author":"M Voortman","year":"2019","journal-title":"Hai"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000501657","article-title":"Quality of life of couples living with sarcoidosis","volume":"98","author":"M Voortman","year":"2019","journal-title":"Respiration"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-2629","article-title":"Characterization of chronic fatigue in patients with sarcoidosis in clinical remission","volume":"140","author":"I HE Korenromp","year":"2011","journal-title":"Chest"},{"key":"ref47","first-page":"PA3274","article-title":"Functional and symptomatic burden of small fiber neuropathy in sarcoidosis","volume":"50","author":"D Culver","year":"2017","journal-title":"Eur Respir J"},{"issue":"03","key":"ref48","first-page":"235","article-title":"The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis","volume":"22","author":"M T Wagner","year":"2005","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2010.09.015","article-title":"Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis","volume":"105","author":"J G Parambil","year":"2011","journal-title":"Respir Med"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"E E Lower","year":"2008","journal-title":"Chest"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"e000394","DOI":"10.1136\/bmjresp-2018-000394","article-title":"First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative","volume":"6","author":"N A Kampstra","year":"2019","journal-title":"BMJ Open Respir Res"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/23120541.00094-2019","article-title":"Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes","volume":"5","author":"N A Kampstra","year":"2019","journal-title":"ERJ Open Res"},{"issue":"02","key":"ref53","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"R P Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref54","first-page":"2","article-title":"Bendstrup. Patient reported outcome measures (PROMs) in sarcoidosis","volume":"34","author":"R FLA Thunold","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"S 02","key":"ref56","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"D L Patrick","year":"2007","journal-title":"Value Health"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11136-013-0438-1","article-title":"A conceptual model of health-related quality of life in sarcoidosis","volume":"23","author":"D E Victorson","year":"2014","journal-title":"Qual Life Res"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s11136-013-0567-6","article-title":"Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis","volume":"23","author":"D E Victorson","year":"2014","journal-title":"Qual Life Res"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11136-017-1738-7","article-title":"Adjusting for cross-cultural differences in computer-adaptive tests of quality of life","volume":"27","author":"C J Gibbons","year":"2018","journal-title":"Qual Life Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5116\/ijme.4dfb.8dfd","article-title":"Making sense of Cronbach's alpha","volume":"2","author":"M Tavakol","year":"2011","journal-title":"Int J Med Educ"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1207\/S15327752JPA8001_18","article-title":"Starting at the beginning: an introduction to coefficient alpha and internal consistency","volume":"80","author":"D L Streiner","year":"2003","journal-title":"J Pers Assess"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1179\/jmt.2008.16.4.82E","article-title":"Clinimetrics corner: the minimal clinically important change Score (MCID): a necessary pretense","volume":"16","author":"C E Cook","year":"2008","journal-title":"J Manual Manip Ther"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jclinepi.2017.06.009","article-title":"Minimal important difference to infer changes in health-related quality of life-a systematic review","volume":"89","author":"R Jayadevappa","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"04","key":"ref64","first-page":"407","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"R Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(00)03562-5","article-title":"Importance of differentiating health status from quality of life","volume":"357","author":"C Bradley","year":"2001","journal-title":"Lancet"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2119\/molmed.2012.00332","article-title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study","volume":"18","author":"L Heij","year":"2012","journal-title":"Mol Med"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/5584_2014_18","article-title":"Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life","volume":"833","author":"D Jastrz\u0119bski","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1477-7525-10-67","article-title":"Distance saturation product predicts health-related quality of life among sarcoidosis patients","volume":"10","author":"J M Bourbonnais","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"01","key":"ref69","first-page":"51","article-title":"The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis","volume":"23","author":"M A Judson","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref70","first-page":"219","article-title":"Clinical impact of inspiratory muscle impairment in sarcoidosis","volume":"21","author":"P Brancaleone","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref71","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"M D Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref72","first-page":"96","article-title":"Effect of gender on health related quality of life in sarcoidosis","volume":"27","author":"J M Bourbonnais","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref73","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The sarcoidosis health questionnaire: a new measure of health-related quality of life","volume":"168","author":"C E Cox","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"J E Ware Jr.","year":"1992","journal-title":"Med Care"},{"issue":"06","key":"ref75","doi-asserted-by":"crossref","first-page":"e0215763","DOI":"10.1371\/journal.pone.0215763","article-title":"Scalp hair cortisol and testosterone levels in patients with sarcoidosis","volume":"14","author":"M JG van Manen","year":"2019","journal-title":"PLoS One"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1300\/J013v30n02_07","article-title":"Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption","volume":"30","author":"J De Vries","year":"1999","journal-title":"Women Health"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0300-2977(98)00148-X","article-title":"Impairment of quality of life: rheumatoid arthritis versus sarcoidosis","volume":"54","author":"R M Wirnsberger","year":"1999","journal-title":"Neth J Med"},{"issue":"01","key":"ref78","first-page":"33","article-title":"Impact of pain in a Dutch sarcoidosis patient population","volume":"20","author":"E Hoitsma","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref79","first-page":"53","article-title":"Does physical training reduce fatigue in sarcoidosis?","volume":"32","author":"R Marcellis","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref80","first-page":"183","article-title":"Quality of life in sarcoidosis: a comparison between members of a patient organisation and a random sample","volume":"15","author":"J De Vries","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref81","first-page":"117","article-title":"Association between physical functions and quality of life in sarcoidosis","volume":"31","author":"M Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref82","first-page":"701","article-title":"WHOQOL-bREF questionnaire as a measure of quality of life in sarcoidosis","volume":"37","author":"M Alilovi\u0107","year":"2013","journal-title":"Coll Antropol"},{"issue":"03","key":"ref83","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1183\/09031936.00117710","article-title":"Exercise capacity, muscle strength and fatigue in sarcoidosis","volume":"38","author":"R G Marcellis","year":"2011","journal-title":"Eur Respir J"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1378\/chest.06-2822","article-title":"Six-minute walk test and health status assessment in sarcoidosis","volume":"132","author":"R P Baughman","year":"2007","journal-title":"Chest"},{"issue":"11","key":"ref85","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.rmed.2008.05.001","article-title":"Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis","volume":"102","author":"B S Gvozdenovic","year":"2008","journal-title":"Respir Med"},{"issue":"07","key":"ref86","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/resp.12359","article-title":"The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis","volume":"19","author":"S de Boer","year":"2014","journal-title":"Respirology"},{"issue":"04","key":"ref87","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5588\/ijtld.12.0665","article-title":"Effect of obesity on patient-reported outcomes in sarcoidosis","volume":"17","author":"B S Gvozdenovic","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"05","key":"ref88","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"M A Judson","year":"2014","journal-title":"Eur Respir J"},{"issue":"07","key":"ref89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"R P Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref90","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"R P Baughman","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"C A McHorney","year":"1993","journal-title":"Med Care"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King's sarcoidosis questionnaire for the assessment of health status","volume":"68","author":"A S Patel","year":"2013","journal-title":"Thorax"},{"issue":"07","key":"ref93","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the sarcoidosis assessment tool. A new patient-reported outcome measure","volume":"191","author":"M A Judson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref94","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"M Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"02","key":"ref95","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"J J Swigris","year":"2010","journal-title":"Respir Med"},{"issue":"21","key":"ref96","doi-asserted-by":"crossref","first-page":"E1260","DOI":"10.1097\/BRS.0000000000002684","article-title":"Minimum clinically important difference in SF-36 scores for use in degenerative cervical myelopathy","volume":"43","author":"J H Badhiwala","year":"2018","journal-title":"Spine"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","article-title":"The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties","volume":"46","year":"1998","journal-title":"Soc Sci Med"},{"issue":"05","key":"ref98","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00520-012-1664-8","article-title":"The minimal clinical important difference in the World Health Organization Quality of Life instrument--100","volume":"21","author":"B L Den Oudsten","year":"2013","journal-title":"Support Care Cancer"},{"issue":"03","key":"ref99","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF quality of life assessment","volume":"28","year":"1998","journal-title":"Psychol Med"},{"key":"ref100","first-page":"PA3002","article-title":"Health-related quality of life and health status among patients with sarcoidosis, chronic obstructive pulmonary disease and interstitial lung disease","volume":"52","author":"M Labor","year":"2018","journal-title":"Eur Respir J"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George's respiratory questionnaire","volume":"85","author":"P W Jones","year":"1991","journal-title":"Respir Med"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire","volume":"145","author":"P W Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"S 01","key":"ref103","first-page":"71","article-title":"[St. George's respiratory questionnaire (SGRQ) in sarcoidosis patients] (in Serbian)","volume":"58","author":"V Zugi\u0107","year":"2005","journal-title":"Med Pregl"},{"issue":"01","key":"ref104","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's respiratory questionnaire: MCID","volume":"2","author":"P W Jones","year":"2005","journal-title":"COPD"},{"issue":"01","key":"ref105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1183\/09031936.94.07010055","article-title":"Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial","volume":"7","author":"P W Jones","year":"1994","journal-title":"Eur Respir J"},{"issue":"03","key":"ref106","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"P W Jones","year":"2002","journal-title":"Eur Respir J"},{"issue":"04","key":"ref107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/09286586.2010.483754","article-title":"Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease","volume":"17","author":"L N Saligan","year":"2010","journal-title":"Ophthalmic Epidemiol"},{"issue":"11","key":"ref108","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1001\/archopht.116.11.1496","article-title":"Psychometric properties of the national eye institute visual function questionnaire (NEI-VFQ)","volume":"116","author":"C M Mangione","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"06","key":"ref109","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archopht.119.6.841","article-title":"Visual functioning and general health status in patients with uveitis","volume":"119","author":"R M Schiffman","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"07","key":"ref110","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item national eye institute visual function questionnaire","volume":"119","author":"C M Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"ref111","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamadermatol.2015.2008","article-title":"Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists","volume":"151","author":"H Yeung","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"03","key":"ref112","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"A Y Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"05","key":"ref113","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"R J Pariser","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"05","key":"ref114","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamadermatol.2013.60","article-title":"Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis","volume":"149","author":"M Rosenbach","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"11","key":"ref115","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"M M Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-3-36","article-title":"Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria","volume":"3","author":"R Shikiar","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"08","key":"ref117","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","article-title":"Measuring health-related quality of life","volume":"118","author":"G H Guyatt","year":"1993","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref118","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"M A Judson","year":"2015","journal-title":"Respir Med"},{"issue":"03","key":"ref119","first-page":"837","article-title":"Health related quality of life regarding to gender in sarcoidosis","volume":"33","author":"A Dudvarski-Ili\u0107","year":"2009","journal-title":"Coll Antropol"},{"issue":"03","key":"ref120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1440-1843.2012.02134.x","article-title":"Validation of the sarcoidosis health questionnaire in a non-US population","volume":"17","author":"S De Boer","year":"2012","journal-title":"Respirology"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.01.001","article-title":"Can the sarcoidosis health questionnaire predict the long-term outcomes in Japanese sarcoidosis patients?","volume":"149","author":"K Tanizawa","year":"2019","journal-title":"Respir Med"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1477-7525-9-34","article-title":"Validation of the Japanese version of the Sarcoidosis Health Questionnaire: a cross-sectional study","volume":"9","author":"K Tanizawa","year":"2011","journal-title":"Health Qual Life Outcomes"},{"issue":"01","key":"ref123","first-page":"75","article-title":"Validation of the King's sarcoidosis questionnaire (KSQ) in a Dutch sarcoidosis population","volume":"33","author":"M J Van Manen","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref124","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12955-019-1131-z","article-title":"Translation and psychometric properties of the King's sarcoidosis questionnaire (KSQ) in German language","volume":"17","author":"E Farin","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"03","key":"ref125","first-page":"313","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"R P Baughman","year":"2017","journal-title":"Hai"},{"issue":"02","key":"ref126","first-page":"9","article-title":"Feasibility of a comprehensive home monitoring program for sarcoidosis","volume":"9","author":"C C Moor","year":"2019","journal-title":"J Pers Med"},{"issue":"03","key":"ref127","first-page":"285","article-title":"Physical inactivity in pulmonary sarcoidosis","volume":"197","author":"P SP Cho","year":"2019","journal-title":"Hai"},{"issue":"02","key":"ref128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/S1806-37562015000000063","article-title":"Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia","volume":"42","author":"V Mihailovi\u0107-Vu\u010dini\u0107","year":"2016","journal-title":"J Bras Pneumol"},{"issue":"01","key":"ref129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"M Drent","year":"2012","journal-title":"Eur Respir J"},{"key":"ref130","first-page":"A4759","article-title":"Standardized translation of the Kings sarcoidosis questionnaire (KSQ) into eleven languages","volume":"195","author":"S Birring","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"ref131","first-page":"P699","article-title":"Assessing sarcoidosis: The King's sarcoidosis questionnaire and the minimal important difference","volume":"40","author":"A S Patel","year":"2012","journal-title":"Eur Respir J"},{"issue":"06","key":"ref132","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ijerph15061077","article-title":"Short-term particulate air pollution exposure is associated with increased severity of respiratory and quality of life symptoms in patients with fibrotic sarcoidosis","volume":"15","author":"C S Pirozzi","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"ref133","first-page":"P413","article-title":"Impact of gender on disease activity, pulmonary function and health status in sarcoidosis patients - King's sarcoidosis questionnaire (KSQ)","volume":"42","author":"B S Gvozdenovic","year":"2013","journal-title":"Eur Respir J"},{"issue":"02","key":"ref134","first-page":"92","article-title":"Fatigue in sarcoidosis: American versus Dutch patients","volume":"26","author":"W P De Kleijn","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS)","volume":"9","author":"J De Vries","year":"2004","journal-title":"Br J Health Psychol"},{"issue":"02","key":"ref136","first-page":"133","article-title":"Psychometric qualities of the fatigue assessment scale in Croatian sarcoidosis patients","volume":"22","author":"H J Michielsen","year":"2005","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13075-019-1864-4","article-title":"the fatigue assessment scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study","volume":"21","author":"A Horisberger","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"05","key":"ref138","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MCP.0000000000000496","article-title":"The fatigue assessment scale: quality and availability in sarcoidosis and other diseases","volume":"24","author":"C Hendriks","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"07","key":"ref139","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3889\/oamjms.2018.242","article-title":"Evaluation of the reliability and validity of the Persian version of the fatigue assessment scale in Iranian sarcoidosis patients","volume":"6","author":"S Lookzadeh","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"issue":"02","key":"ref140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial","volume":"45","author":"E E Lower","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"02","key":"ref141","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.2044-8287.2012.02094.x","article-title":"Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis","volume":"18","author":"W P de Kleijn","year":"2013","journal-title":"Br J Health Psychol"},{"issue":"09","key":"ref142","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.rmed.2011.05.004","article-title":"Minimal (clinically) important differences for the fatigue assessment scale in sarcoidosis","volume":"105","author":"W P de Kleijn","year":"2011","journal-title":"Respir Med"},{"issue":"06","key":"ref143","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jpsychores.2011.09.006","article-title":"Types of fatigue in sarcoidosis patients","volume":"71","author":"W P De Kleijn","year":"2011","journal-title":"J Psychosom Res"},{"issue":"05","key":"ref144","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MCP.0b013e32832d0403","article-title":"Fatigue in sarcoidosis: a systematic review","volume":"15","author":"W P de Kleijn","year":"2009","journal-title":"Curr Opin Pulm Med"},{"issue":"04","key":"ref145","first-page":"407","article-title":"Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability","volume":"197","author":"C MR Hendriks","year":"2019","journal-title":"Hai"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2016.05.010","article-title":"Predictors of fatigue in sarcoidosis: the value of exercise testing","volume":"116","author":"B Strookappe","year":"2016","journal-title":"Respir Med"},{"issue":"01","key":"ref147","first-page":"65","article-title":"Type D or \u2018distressed\u2019 personality in sarcoidosis and idiopathic pulmonary fibrosis","volume":"28","author":"M D Elfferich","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref148","first-page":"57","article-title":"Relationship between perceived stress and sarcoidosis in a Dutch patient population","volume":"21","author":"J De Vries","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/jocn.12490","article-title":"The relationship between physical activity, functional performance and fatigue in sarcoidosis","volume":"23","author":"L N Saligan","year":"2014","journal-title":"J Clin Nurs"},{"issue":"02","key":"ref150","first-page":"127","article-title":"The relationship between fatigue and clinical parameters in pulmonary sarcoidosis","volume":"21","author":"J De Vries","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"07","key":"ref151","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4187\/respcare.02080","article-title":"Factors associated with fatigue in sarcoidosis","volume":"59","author":"M Fleischer","year":"2014","journal-title":"Respir Care"},{"issue":"05","key":"ref152","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.genhosppsych.2011.05.009","article-title":"Fatigue in patients with sarcoidosis, compared with the general population","volume":"33","author":"A Hinz","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"issue":"01","key":"ref153","first-page":"60","article-title":"The internal consistency of PRO fatigue instruments in sarcoidosis: superiority of the PFI over the FAS","volume":"30","author":"A Kalkanis","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref154","first-page":"247","article-title":"Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study","volume":"191","author":"R G Marcellis","year":"2013","journal-title":"Hai"},{"issue":"01","key":"ref155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5603\/PiAP.2015.0002","article-title":"Fatigue in patients with inactive sarcoidosis does not correlate with lung ventilation ability or walking distance. Pilot Study","volume":"83","author":"K Ziele\u017anik","year":"2015","journal-title":"Pneumonol Alergol Pol"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"6853948","DOI":"10.1155\/2018\/6853948","article-title":"Daytime sleepiness in patients diagnosed with sarcoidosis compared with the general population","volume":"2018","author":"A Hinz","year":"2018","journal-title":"Can Respir J"},{"issue":"04","key":"ref157","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1034\/j.1399-3003.1999.13d03.x","article-title":"Association of fatigue with an acute phase response in sarcoidosis","volume":"13","author":"M Drent","year":"1999","journal-title":"Eur Respir J"},{"issue":"03","key":"ref158","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","article-title":"The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue","volume":"39","author":"E M Smets","year":"1995","journal-title":"J Psychosom Res"},{"issue":"04","key":"ref159","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000092670","article-title":"Relationship between symptoms and quality of life in a sarcoidosis population","volume":"74","author":"H J Michielsen","year":"2007","journal-title":"Respiration"},{"issue":"02","key":"ref160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-2977(98)00058-8","article-title":"Clinical presentation of sarcoidosis in the Netherlands an epidemiological study","volume":"53","author":"R M Wirnsberger","year":"1998","journal-title":"Neth J Med"},{"issue":"04","key":"ref161","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4187\/respcare.04312","article-title":"Effects of inspiratory muscle training in subjects with sarcoidosis: a randomized controlled clinical trial","volume":"61","author":"M N Karadall\u0131","year":"2016","journal-title":"Respir Care"},{"issue":"02","key":"ref162","first-page":"139","article-title":"Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea","volume":"29","author":"A Hinz","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref163","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1752-699X.2010.00214.x","article-title":"Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis","volume":"5","author":"A Baydur","year":"2011","journal-title":"Clin Respir J"},{"issue":"01","key":"ref164","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.120.1.102","article-title":"Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis","volume":"120","author":"A Baydur","year":"2001","journal-title":"Chest"},{"issue":"06","key":"ref165","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"M A Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"ref166","first-page":"1179","article-title":"Reduction of exercise capacity in sarcoidosis in relation to disease severity","volume":"9","author":"A Kallianos","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"01","key":"ref167","first-page":"46","article-title":"A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society study of long-term corticosteroid treatment","volume":"14","author":"M F Muers","year":"1997","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref168","first-page":"A5609","article-title":"Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients","volume":"199","author":"O N Obi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref169","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000079641","article-title":"Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis","volume":"71","author":"W G Barros","year":"2004","journal-title":"Respiration"},{"issue":"01","key":"ref170","first-page":"46","article-title":"Efficacy Results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"N J Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref171","first-page":"43","article-title":"Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study","volume":"32","author":"B Strookappe","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"05","key":"ref172","first-page":"701","article-title":"Benefits of Physical Training in Sarcoidosis","volume":"193","author":"B Strookappe","year":"2015","journal-title":"Hai"},{"issue":"05","key":"ref173","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1378\/chest.130.5.1496","article-title":"Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis","volume":"130","author":"H J Kabitz","year":"2006","journal-title":"Chest"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bmj.2.6132.241","article-title":"Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease","volume":"2","author":"C R McGavin","year":"1978","journal-title":"BMJ"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/bmj.2.5147.257","article-title":"The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population","volume":"2","author":"C M Fletcher","year":"1959","journal-title":"BMJ"},{"issue":"06","key":"ref176","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/occmed\/kqx086","article-title":"The MRC breathlessness scale","volume":"67","author":"N Williams","year":"2017","journal-title":"Occup Med (Lond)"},{"issue":"03","key":"ref177","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"D A Mahler","year":"1988","journal-title":"Chest"},{"issue":"06","key":"ref178","first-page":"751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"D A Mahler","year":"1984","journal-title":"Chest"},{"issue":"10","key":"ref179","doi-asserted-by":"crossref","first-page":"e0205308","DOI":"10.1371\/journal.pone.0205308","article-title":"Psychometric properties of the German version of the Leicester cough questionnaire in sarcoidosis","volume":"13","author":"J C Schupp","year":"2018","journal-title":"PLoS One"},{"issue":"01","key":"ref180","first-page":"21","article-title":"Cough in sarcoidosis","volume":"194","author":"T Tully","year":"2016","journal-title":"Hai"},{"issue":"05","key":"ref181","first-page":"587","article-title":"The assessment of cough in a sarcoidosis clinic using a validated instrument and a visual analog scale","volume":"195","author":"M A Judson","year":"2017","journal-title":"Hai"},{"issue":"05","key":"ref182","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1183\/13993003.01369-2015","article-title":"Predictors of objective cough frequency in pulmonary sarcoidosis","volume":"47","author":"A Sinha","year":"2016","journal-title":"Eur Respir J"},{"issue":"04","key":"ref183","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester cough questionnaire (LCQ)","volume":"58","author":"S S Birring","year":"2003","journal-title":"Thorax"},{"issue":"05","key":"ref184","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1183\/09031936.00057407","article-title":"The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough","volume":"31","author":"S S Birring","year":"2008","journal-title":"Eur Respir J"},{"issue":"S 07","key":"ref185","first-page":"S728","article-title":"An update on measurement and monitoring of cough: what are the important study endpoints?","volume":"6","author":"A Spinou","year":"2014","journal-title":"J Thorac Dis"},{"issue":"07","key":"ref186","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbi.2011.06.004","article-title":"Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue","volume":"25","author":"I H Korenromp","year":"2011","journal-title":"Brain Behav Immun"},{"issue":"02","key":"ref187","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpsychores.2011.10.001","article-title":"Post-inflammatory fatigue in sarcoidosis: personality profiles, psychological symptoms and stress hormones","volume":"72","author":"I H Korenromp","year":"2012","journal-title":"J Psychosom Res"},{"issue":"07","key":"ref188","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1183\/09031936.97.10071450","article-title":"Relationship between respiratory muscle function and quality of life in sarcoidosis","volume":"10","author":"R M Wirnsberger","year":"1997","journal-title":"Eur Respir J"},{"issue":"02","key":"ref189","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1479972316661926","article-title":"Managing fatigue in sarcoidosis - a systematic review of the evidence","volume":"14","author":"C Atkins","year":"2017","journal-title":"Chron Respir Dis"},{"issue":"04","key":"ref190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0037-1602589","article-title":"Quality of life in sarcoidosis","volume":"38","author":"M A Judson","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"issue":"04","key":"ref191","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1378\/chest.15-0584","article-title":"Interrelationship between sleep-disordered breathing and sarcoidosis","volume":"148","author":"C Lal","year":"2015","journal-title":"Chest"},{"issue":"02","key":"ref192","first-page":"159","article-title":"The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients","volume":"13","author":"A Pietinalho","year":"1996","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref193","first-page":"267","article-title":"Non-specific bronchial reactivity and ultrastructure of the airway epithelium in patients with sarcoidosis and allergic alveolitis","volume":"131","author":"L A Laitinen","year":"1983","journal-title":"Eur J Respir Dis Suppl"},{"issue":"02","key":"ref194","first-page":"118","article-title":"Aspecific bronchial hyperreactivity in pulmonary sarcoidosis","volume":"11","author":"S Marcias","year":"1994","journal-title":"Sarcoidosis"},{"issue":"03","key":"ref195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000196408","article-title":"Sarcoidosis patients have bronchial hyperreactivity and signs of mast cell activation in their bronchoalveolar lavage","volume":"62","author":"M B Ohrn","year":"1995","journal-title":"Respiration"},{"issue":"02","key":"ref196","first-page":"154","article-title":"Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients","volume":"19","author":"M M Lewis","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref197","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1164\/ajrccm.163.2.ed2000b","article-title":"Examining the link between sarcoidosis and depression","volume":"163","author":"J R Curtis","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"14","key":"ref198","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.0b013e3181bacf05","article-title":"Intraepidermal nerve fiber density and its application in sarcoidosis","volume":"73","author":"M Bakkers","year":"2009","journal-title":"Neurology"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(02)08912-2","article-title":"Small fibre neuropathy in sarcoidosis","volume":"359","author":"E Hoitsma","year":"2002","journal-title":"Lancet"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"J O Tavee","year":"2017","journal-title":"Respir Med"},{"issue":"06","key":"ref201","doi-asserted-by":"crossref","first-page":"BIO52","DOI":"10.1167\/iovs.16-21291","article-title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","volume":"58","author":"D A Culver","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"08","key":"ref202","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db07-0285","article-title":"Surrogate markers of small fiber damage in human diabetic neuropathy","volume":"56","author":"C Quattrini","year":"2007","journal-title":"Diabetes"},{"issue":"01","key":"ref203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rmed.2010.09.014","article-title":"The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis","volume":"105","author":"E Hoitsma","year":"2011","journal-title":"Respir Med"},{"issue":"01","key":"ref204","first-page":"73","article-title":"Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab","volume":"23","author":"E Hoitsma","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"A Dahan","year":"2013","journal-title":"Mol Med"},{"issue":"04","key":"ref206","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.2014.892072","article-title":"ARA 290 for treatment of small fiber neuropathy in sarcoidosis","volume":"23","author":"M van Velzen","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/5584_2017_85","article-title":"Physical functioning and symptoms of chronic fatigue in sarcoidosis patients","volume":"1040","author":"K Pilzak","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"02","key":"ref208","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial","volume":"38","author":"I Naz","year":"2018","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"02","key":"ref209","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000328796","article-title":"Disfiguring annular sarcoidosis improved by adalimumab","volume":"3","author":"C A Kaiser","year":"2011","journal-title":"Case Rep Dermatol"},{"issue":"05","key":"ref210","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.sleep.2014.12.025","article-title":"Subjective sleep quality in sarcoidosis","volume":"16","author":"A Bosse-Henck","year":"2015","journal-title":"Sleep Med"},{"issue":"02","key":"ref211","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.psychres.2008.04.022","article-title":"An assessment of the CES-D scale factor structure in black women: The Black Women's Health Study","volume":"168","author":"K H Makambi","year":"2009","journal-title":"Psychiatry Res"},{"issue":"02","key":"ref212","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000477352","article-title":"Fatigue and excessive daytime sleepiness in sarcoidosis: prevalence, predictors, and relationships between the two symptoms","volume":"94","author":"A Bosse-Henck","year":"2017","journal-title":"Respiration"},{"issue":"04","key":"ref213","first-page":"282","article-title":"Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis","volume":"30","author":"P Holas","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref214","first-page":"A4752","article-title":"A double blind, placebo controlled study of roflumilast to prevent acute events in fibrotic sarcoidosis","volume":"195","author":"P Baughman","year":"2017","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1710080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T23:00:18Z","timestamp":1597100418000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1710080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":213,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1710080","relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}